Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-05-11

Clinical Trial Update: XP13512 vs. Placebo in Patients With Restless Legs Syndrome. [Phase 3]

View source ↗

Summary

Phase 3 trial comparing XP13512 (gabapentin enacarbil) to placebo in restless legs syndrome has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Horizant (gabapentin enacarbil)

Snippet

Sponsor: XenoPort, Inc. | Conditions: Restless Legs Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2011-05-11